SynthesisKidney & blood pressure research2026
Mortality and Cardiovascular Outcomes Associated with Statin Use in Dialysis Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
Synthesis in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDialysis patients with established atherosclerotic cardiovascular disease (ASCVD) face exceptionally high risks of mortality and recurrent cardiovascular events yet remain substantially underrepresented in major statin trials. We aimed to synthesize evidence from studies restricted to this population to evaluate the association between statin therapy and clinical outcomes.
methodsWe systematically searched Embase, MEDLINE, Web of Science, Scopus, and CENTRAL databases from inception through February 20, 2025, for randomized controlled trials and observational studies evaluating statin therapy in adults receiving maintenance dialysis with documented ASCVD. Hazard ratios were pooled using random-effects models. Risk of bias was assessed using the ROBINS-I tool. The primary outcome was all-cause mortality.
resultsFourteen cohort studies comprising 242,118 patients were included in the meta-analysis. Statin therapy was associated with a significant reduction in all-cause mortality (HR 0.85, 95% CI: 0.74-0.98; p = 0.027; I2 = 53.1%). Associations with cardiac mortality (HR 0.88, 95% CI: 0.66-1.16; I2 = 79.6%) and major adverse cardiovascular events (HR 0.85, 95% CI: 0.59-1.21; I2 = 61.8%) were not statistically significant. Leave-one-out sensitivity analyses supported the robustness of the primary finding. Among dialysis patients with established ASCVD, the proportion of statin-treated patients was 35% and increased over time.
conclusionAmong dialysis patients with established ASCVD, statin therapy is associated with lower all-cause mortality; however, its effect on cardiovascular outcomes remains uncertain. Substantial heterogeneity and a predominance of observational evidence limit causal inference. Well-designed prospective trials in this high-risk population are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.